Results 81 to 90 of about 23,180 (193)

Natural history of a visceral leishmaniasis outbreak in highland Ethiopia [PDF]

, 2009
In May 2005, visceral leishmaniasis (VL) was recognized for the first time in Libo Kemken, Ethiopia, a highland region where only few cases had been reported before. We analyzed records of VL patients treated from May 25, 2005 to December 13, 2007 by the
Alvar, J, Aparicio, P, Argaw, D, Bashaye, S, Bern, C, Bernal, O, Flevaud, L, Herrero, M, Lima, M A, Mulugeta, A, Orfanos, G, Palma, P P, Parreño, F, Pedraza, J, Rubens, D   +14 more
core   +1 more source

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis. [PDF]

, 2017
Visceral leishmaniasis is a neglected tropical disease that causes significant morbidity and mortality worldwide. Characterization of the pharmacokinetics and pharmacodynamics of antileishmanial drugs in preclinical models is important for drug ...
Croft, Simon L, Harris, Andy, Qaiser, Zeeshan, Seifert, Karin, Voak, Andrew A   +4 more
core   +2 more sources

Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates.

PLoS ONE, 2017
We studied 19 cases of proven/probable mucormycosis diagnosed from 2007 to 2015 in our hospital and assessed the microbiological characteristics of the isolates.
Jesús Guinea, Pilar Escribano, Antonio Vena, Patricia Muñoz, María Del Carmen Martínez-Jiménez, Belén Padilla, Emilio Bouza   +6 more
doaj   +1 more source

Cost‐Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United Kingdom

Mycoses, Volume 69, Issue 2, February 2026.
ABSTRACT Background Invasive candidiasis (IC), life‐threatening fungal infections with high economic burden, are often treated first‐line with daily intravenous echinocandins. A new once weekly echinocandin, rezafungin, demonstrated statistically non‐inferior efficacy and numerically shorter intensive care unit (ICU) stay compared to caspofungin in ...
Noemi Muszbek, Alisha Angdembe, Carolina Garcia‐Vidal, Inga Bielicka, Keith R. Abrams, Keith Tolley, Markus Ruhnke, Maximilian Lebmeier, Neil Hawkins, Nick Manamley, Sara Dickerson   +10 more
wiley   +1 more source

Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real‐World Clinical Practice

Mycoses, Volume 69, Issue 2, February 2026.
ABSTRACT Background Echinocandins are the first‐line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once‐weekly intravenous administration, offering potential advantages in complex clinical settings.
Jorge Boán, Eduardo Aparicio‐Minguijón, Mario Fernández‐Ruiz, María Asunción Pérez‐Jacoiste Asín, Isabel Rodríguez‐Goncer, Francisco López‐Medrano, Rafael San‐Juan, José Tiago Silva, Ana Pérez‐Ayala, Jose Manuel Caro‐Teller, José María Aguado   +10 more
wiley   +1 more source

Fungal Meningitis in an Immunocompetent Patient [PDF]

, 2013
Cryptococcal meningitis is a rare entity among immunocompetent hosts but, when it occurs, it is associated with significant morbidity and mortality.
Faria, D., Ferreira, R., Louro, R., Monteiro, E., Parada, H., Pinheiro, C.   +5 more
core   +1 more source

Fungal infections of the central nervous system: A review of fungal pathogens and treatment [PDF]

, 2007
Multiple factors influence the outcome of fungal infection of the central nervous system (CNS). The host and the pathogen in concert with drug delivery across the blood-brain barrier and drug activity are key factors in outcome.
Dancer, C., Redmond, A., Woods, M. L.
core   +1 more source

High-dose amphotericin: yay or nay? A case series and literature review

Drugs in Context
Invasive fungal infections pose significant morbidity and mortality risks, particularly those caused by moulds. Available antifungal classes are limited by toxicities and are increasingly susceptible to resistance, particularly amongst challenging fungal
Kayla R Stover, Taylor E Jordan, Jamie L Wagner, Katie E Barber   +3 more
doaj   +1 more source

Reversible Ototoxicity: A Rare Adverse Reaction of Liposomal Amphotericin-B Used for the Treatment of Antimony-Resistant Visceral Leishmaniasis in an Elderly Male

Clinical Medicine Insights: Case Reports, 2014
Amphotericin-B, a broad spectrum antifungal agent, has been known to cause adverse effects such as nephrotoxicity and infusion-related side effects such as fever, chills, rigor, and arthralgias. However, ototoxicity as an adverse effect of Amphotericin-B
PC Das, Ramesh Kandel, Kapil Sikka, AB Dey   +3 more
doaj   +1 more source

Development and deployment of a solid oral amphotericin B dosage form to treat visceral leishmaniasis within a pediatric population.

PLoS Neglected Tropical Diseases
Visceral leishmaniasis (VL) is a severe and potentially fatal infection, with over 90% of reported cases occurring in East African countries including Chad, Djibouti, Eritrea, Ethiopia, Kenya, Somalia, South Sudan, Sudan, and Uganda, affecting mainly ...
Kishor M Wasan
doaj   +1 more source